Platelet PDGF and TGF-βLevels in Myeloproliferative Disorders
- 1 January 1991
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 6 (1) , 1-6
- https://doi.org/10.3109/10428199109064872
Abstract
Myeloproliferative disorders mainly including essential thrombocythemia, polycythemia vera, chronic myeloid leukemia and myelofibrosis with myeloid metaplasia are clonal myeloproliferative diseases in which myelofibrosis is commonly observed. The pathogenesis of myelofibrosis still remains unclear. However it was proposed that an inappropriate release of PDGF from either megakaryocytes in bone marrow or platelets in circulation might promote medullary fibrosis. Recently the role of another peptide growth factor, namely TGF-β, in the fibrotic process was emphasized. This review will focus on the different studies aimed at the evaluation of intraplatelet PDGF and TGF-β content in patients with the various MPD, and outline the salient results lending support to the potential role of PDGF and TGF-β in the promotion of myelofibrosis.Keywords
This publication has 34 references indexed in Scilit:
- Transforming Growth Factors β1 and α in Chronic Liver DiseaseNew England Journal of Medicine, 1991
- Interferon‐γin vivo reverses the increased platelet levels of platelet‐derived growth factor and transforming growth factor‐β in patients with myelofibrosis with myeloid metaplasiaBritish Journal of Haematology, 1991
- Abnormal Levels of Platelet-Specific Proteins and Mitogenic Activity in Myeloproliferative DiseaseActa Haematologica, 1991
- A reversible defect of platelet PDGF content in myeloproliferative disordersBritish Journal of Haematology, 1988
- Platelet‐derived growth factor is decreased in patients with myeloproliferative disordersAmerican Journal of Hematology, 1988
- Platelet function in myeloproliferative disorders: Characterization and sequential studies show multiple platelet abnormalities, and change with timeEuropean Journal of Haematology, 1988
- Composition of immune complexes and their relation to plasma fibronectin in chronic myeloproliferative disorders.Journal of Clinical Pathology, 1987
- REDUCED PLATELET MITOGENIC ACTIVITY IN MYELOPROLIFERATIVE DISORDERSThe Lancet, 1986
- The biology of platelet-derived growth factorCell, 1986
- Platelet‐derived growth factor(s) mitogenic activity in patients with myeloproliferative diseaseBritish Journal of Haematology, 1986